23andMe Investor Presentation Deck

Pharmaceutical Industry 7 years average time-to-IND¹ ~90% failure rate² 23andMe ~4-5 years to IND with current clinical-stage drugs Targets with genetic evidence have historically had a higher success rate³ Publications supporting human genetic evidence for approved drug indications Nelson et al., 2015 (Nature Genetics); King et al., 2019 (PLOS Genetics) ¹ IND = Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2 Probability of success for a drug to be approved is estimated to be <12%. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). 3 Nelson et al., 2015 (Nature Genetics), King et al., 2019 (PLOS Genetics) Potential to More Efficiently Develop Novel Therapeutics by "Power, Need, and Speed" 27

View entire presentation